Plenary Program

Day 1: Cancer Biology

Morning Plenary Session: Genomics & Proteomics

1. Risks assessment & cancer control strategies
   HU Vainio (IARC)
2. Multifactorial predisposition & gene expression
   H Lynch (Omaha, NE)
3. Tobacco oncogenesis & nicotine metabolism
   RF Tyndale (U Toronto)
4. Histone modification enzymes
   FJ Rauscher III (Wistar, Philadelphia)
5. Nutritional genomics & epigenetics
   TBA
6. Circuitry of cancer
   WC Hahn (Harvard MS)

Keynote

• Diet influence in oncogenesis & therapy
  JH Weisburger (Am Health Fndn)

Afternoon Plenary Session: Chronic Inflammation

1. Cell mediated immunity & angiogenesis
   RD Schreiber (St Louis)
2. Pre-malignant chemoprevention
   H Bartsch (DKZ, Heidelberg)
3. HPV & neoplasia
   M Saveria Campo (Glasgow)
4. H. pylori & gastric cancer
   TBA
5. Photocarcinogenesis & cutaneous melanoma
   FO Nestle (Switzerland)
6. Hepatitis B & C & hepatocellular carcinoma
   ZT Sun (Beijing)

Day 2: Cancer Prevention

Morning Plenary Session: Strategies

1. High-risk groups & measurement
   M Fenech (CSIRO, Adelaide)
2. Smoking-related cancer & premalignant markers
   TBA
3. Molecular targets: prostate cancer
   R Liebermann (NCI, Bethesd)
4. Molecular targets: breast cancer
   R Brentani (Ludwig, Sao Paulo)
5. Chemopreventive agents: identification & validation
   HU Vainio (IARC)
6. Vaccines
   J Schlom (NCI, Bethesda)

Keynote

• National Cancer Control Programs: best way to reduce cancer burden
  C Sepulveda (WHO)

Afternoon Plenary Session: Risk Avoidance & Reduction

1. Tobacco control programs (incl legislation)
   TBA
2. Environmental & genotoxic exposures
   P Vineis (Turin)
3. Endocrine disrupters
   CW Chen (NATO)
4. Physical activity & weight control
   TBA
5. Ionizing radiation exposure
   D Krewski (Ottawa)
6. Sunscreens & skin cancer - public education
   TBA

Day 3: Cancer Screening

Morning Plenary Session: Challenges

1. PAP smear screening: mid-income countries
   C Sepulveda (WHO)
2. HPV-DNA-based programs
   FX Bosch (Barcelona)
3. VIA-based programs
   R Sankaranarayanan (IARC)
4. Public awareness & acceptance
   T Sullivan (Toronto)
5. Health technology assessment
   TBA
6. Cancer surveillance - bioethics, legislation
   PA Singer (Toronto)

Keynote

• Cancer prevention research & cancer control strategies
  S Sutcliffe (CSCC)

Afternoon Plenary Session: Controversies

1. Lung screening - US NLST & implications
   TBA
2. Mammography, BSE, CBE
   TBA
3. Prostate - PSA testing
   R Lieberman (NCI Bethesda)
4. Colorectal cancer screening
   H Bryant (Alberta Cancer Board)
5. Assessment of intraepithelial lesions
   TH van der Kwast (Rotterdam)
6. Controversies
   AB Miller (Toronto)

Day 4: Cancer Intervention

Morning Plenary Session: Strategies

1. Signal transduction inhibitors & MDR
   TBA
2. Antioxidants: mitochondria induction of apoptosis
   TBA
3. Gap junctions targets & chemoprevention
   G Batist (McGill)
4. Tyrosine kinase inhibitors
   TBA
5. Topoisomerase inhibitors
   WT Beck (Chicago)
6. EGFR inhibitors
   TBA

Keynote

• Translational Research
  N Bruchovsky

Afternoon Plenary Session: Therapies

1. Management of precursor lesions
   DS Alberts (Arizona)
2. Immunotherapy of malignant melanoma
   TBA
3. Hematologic malignancies
   HT Lynch (Omaha)
4. Stem cell gene therapy
   S Ikehara (Osaka)
5. Combination therapy
   E Eisenhauer (Queens U)